All relevant data have been uploaded to figshare and are accessible using the following links: <https://figshare.com/s/24b5874c8a5af59ebd49> and <https://figshare.com/s/7088c82c63226b888a67>.

Introduction {#sec006}
============

HIV/AIDS remains a global health concern despite considerable resources that have been allocated in the past twenty years. Globally in 2017, 36.9 million people were living with HIV \[[@pone.0225476.ref001],[@pone.0225476.ref002]\]. Since 2014, there has been a renewed commitment to fight HIV with the joint United Nations programme on HIV/AIDS (UNAIDS) launching the 90-90-90 targets with a view to end the HIV/AIDS epidemic by 2030 \[[@pone.0225476.ref003]\]. The third '90' requires that by 2020, 90% of those on antiretroviral therapy (ART) are virally suppressed (\<1000 copies per ml of plasma). In 2016, the World Health Organization (WHO) emphasized scaling up of viral load (VL) testing access in ART programmes in low- and middle-income countries, with pregnant and breastfeeding (PBF) women on ART being one of priority groups \[[@pone.0225476.ref004]\].

In 2017, 180 000 (10%) of the 1.8 million new HIV infections were amongst children \[[@pone.0225476.ref002]\]. More than 90% of children living with HIV acquire infection through mother-to-child transmission (MTCT) \[[@pone.0225476.ref005]\]. Half of all MTCT occurs during breastfeeding \[[@pone.0225476.ref006],[@pone.0225476.ref007]\]. Unlike in general population, there is a limited window period during PBF period to institute HIV prevention interventions as each additional week of uncontrolled viremia increases MTCT risk \[[@pone.0225476.ref006],[@pone.0225476.ref008]\]. The high risk stratification factors for MTCT are maternal VL over 1000 copies/ml at ≥32 weeks gestation, newly diagnosed HIV+ mothers during labour/delivery and breastfeeding period, incident infection (sero-conversion) during PBF, no ART or \< 8 weeks of ART at delivery \[[@pone.0225476.ref004]\]. Therefore, it is important to understand the uptake and turnaround time (TAT) for VL testing in PBF women.

In 2017, access to VL testing remained low with a quarter of the countries reporting less than 50% uptake among those on ART \[[@pone.0225476.ref009]\]. Swannet et al noted 40% uptake among general population in Mozambique and factors associated with uptake included age, longer ART duration and differentiated service delivery services \[[@pone.0225476.ref010]\]. Among PBF women on ART, there is limited evidence on uptake and TAT for VL testing and VL suppression especially during breastfeeding. In Malawi, 84% VL suppression was reported in a randomised controlled trial among PBF women who underwent VL testing after six months of ART and longer ART duration was associated with viral suppression at child birth \[[@pone.0225476.ref011]\].

Zimbabwe, a low income country in Southern Africa and has a high HIV prevalence (14% among 15--49 years in general population). Since 2013, the country implemented option B+ for PBF women (lifelong ART among PBF women living with HIV irrespective of the WHO clinical stage) and since 2015, routine VL testing for monitoring of response to ART was initiated. In 2015--16, the population-based 'ZIMPHIA' survey reported that 60% of people living with HIV were virally suppressed (65% among women living with HIV) \[[@pone.0225476.ref012]\]. There is paucity of data regarding VL monitoring among PBF women in Zimbabwe. Hence, we conducted this operational research to assess the uptake and turnaround time (TAT) for VL testing amongst women on 'option B+' in a rural district in Zimbabwe in 2017. Additionally, we assessed the factors associated with HIV VL testing uptake.

Methods {#sec007}
=======

Study design {#sec008}
------------

This was a cohort study using routinely collected secondary data.

Setting {#sec009}
-------

### General setting {#sec010}

Zimbabwe is a landlocked country divided into 10 provinces and 63 districts with a population of 13 million. Majority of the population (67%) lives in rural areas \[[@pone.0225476.ref013]\]. Approximately 95% of health facilities in Zimbabwe are public institutions providing both preventive and curative health services with free treatment available for HIV, TB, malaria and maternal and child health. According to the Zimbabwe demographic health survey in 2015, ninety three percent women aged 15--49 years received antenatal care (ANC) by a skilled provider and 72% of deliveries were conducted by a skilled provider \[[@pone.0225476.ref014]\]. In 2017, around 63 000 women living with HIV went for ANC and 90% of them were on ART \[[@pone.0225476.ref015]\].

Mazowe is a rural district in Mashonaland Central Province with a population of 0.23 million \[[@pone.0225476.ref013]\]. The public health facilities include three hospitals (one of them is district hospital) and 25 rural health clinics offering HIV prevention and treatment services (including prevention of mother to child transmission (PMTCT) services).

### PMTCT programme {#sec011}

The ANC registration process involves manual recording of baseline demographic data of patients in the ANC register and issuing of a booking card. Child birth related details are filled in a delivery register. All pregnant women who are not living with HIV are offered HIV testing. Women found to be positive for HIV during ANC are initiated on ART, which is dispensed in ANC clinics with information being manually recorded in ANC register, ART register, and ART patient care booklet. ANC visits and ART visits are synchronised. For women already on ART, the ART patient care booklet is shifted from ART clinic to ANC clinic for a maximum period of two years post child birth. HIV exposed infant register is also maintained to record HIV prophylaxis, testing and follow up. The collected data from health facility registers is aggregated into a monthly return form that is sent to the district for data entry into the district health information system.

The national PMTCT programme mimics other national programmes in the region. The PMTCT programme has a national plan to eliminate MTCT of HIV and syphilis by 2022 \[[@pone.0225476.ref016]\]. The PMTCT programme provides a differentiated care service in the monitoring of VL among PBF women who are either ART naïve or already on ART. For ART naive PBF women, the first specimen for VL is taken after 3 months on ART. For those already on ART, if VL was not done within the last 6 months, it is done at the first ANC visit. If found to be virally non-suppressed, VL testing is repeated after conducting enhanced adherence counselling **([Fig 1](#pone.0225476.g001){ref-type="fig"})**.

![National algorithm for viral load testing among pregnant and breast feeding women living with HIV in Zimbabwe (2017).\
HIV--Human immunodeficiency virus; ART-Antiretroviral therapy; VL- Viral Load; FDC-Fixed dose combination; ANC-Antenatal care.](pone.0225476.g001){#pone.0225476.g001}

Dried blood spot (DBS) and/or venous blood specimen (in ethylene diamine tetra-acetic acid vials) are sent to the national microbiology reference laboratory in Harare (maximum distance 72km) twice a week by a human carrier as a part of integrated specimen transportation. The results follow a similar route from testing laboratory back to the health facility. At facility level, VL register and ART care booklet are used to record date of specimen collection and VL result receipt.

Patient population {#sec012}
------------------

Pregnant women living with HIV and having their first ANC visit in public health facilities in 2017 in Mazowe district were the patient population. The pregnancy cohort included pregnant women who were i) already on ART or ii) ART naïve at the time of first ANC visit and completed three months of ART.

Data variables, sources of data and data collection {#sec013}
---------------------------------------------------

Between December 2018 and March 2019, data were collected from routine health facility registers (ANC register, ART booklet, delivery register and HIV exposed infant register) into a structured paper-based data collection form. Baseline characteristics included demographic data and antenatal care and HIV care related data. For ART naïve patients, information collected included date of HIV diagnosis and ART initiation. Dates of child birth, status of child and ART status of mother at six months post child birth, dates for VL testing and dates for VL result receipt by PBF women were obtained. Data on any VL results available at the facility during pregnancy and/or breastfeeding (up to six months post child birth) were collected. VL uptake was defined as when sample was collected and result was available at the clinic (irrespective of the result including invalid results).

Analysis and statistics {#sec014}
-----------------------

Data were single-entered and analyzed using EpiData (version 4.1.1.0 for entry and version 2.2.2.183 for analysis, EpiData Association, Odense, Denmark). Adjusted analysis was performed using STATA (version 12.1 STATA Corp., College Station, TX, USA).

Baseline demographic, clinical and programmatic characteristics at ANC registration were summarized using frequency (proportion) and mean (standard deviation---SD) as applicable. Uptake of any VL test and availability of VL result after 32 weeks of gestation among the pregnancy cohort was reported using proportions (95% confidence interval (CI)).

The TAT in days from sending the specimen to receipt of result by PBF mother was summarised using median and interquartile range (IQR). Factors associated with uptake of VL test in the pregnancy cohort were summarized (inferred) using crude and adjusted relative risks (95% CI). Modified Poisson regression using robust variance estimates was used for the adjusted analysis. Factors with crude p\<0.2 were included in the regression model.

Ethics {#sec015}
------

Administrative approval for the study was obtained from Ministry of Health and Child Care AIDS and TB programme. Ethics approval was obtained from Medical Research Council of Zimbabwe (MRCZ/E/227, dated 06/12/2018) and The Union Ethics Advisory Group, Paris, France (EAG-55/18, dated 29/09/2018). As part of the ethics application, waiver for informed consent was sought and approved since the study involved review of secondary programme data.

Results {#sec016}
=======

Baseline characteristics {#sec017}
------------------------

There were 1359 pregnant women living with HIV who registered for ANC in 2017 and of them 1112 formed the pregnancy cohort and were included in the study. There was missing data for 242 women **([Fig 2](#pone.0225476.g002){ref-type="fig"})**. The baseline characteristics of the pregnancy cohort are summarized in **[Table 1](#pone.0225476.t001){ref-type="table"}**. Of 1112, a total of 112 (10%) were ART naïve whilst 1000 (90%) were already on ART at ANC registration. The mean (SD) age and gestational age in weeks at ANC registration was 30.3 (6.1) years and 18.8 (7.1) weeks, respectively.

![Flowchart describing the pregnancy cohort included in this study, Mazowe district, Zimbabwe (2017).\
VL--Viral load; ANC- Antenatal Care; ART-Antiretroviral treatment. In the pregnancy cohort, women already on ART were eligible for VL testing at ANC registration if VL results were not available in the previous six months. Women newly initiated on ART were eligible for first VL testing after completing three months of ART.](pone.0225476.g002){#pone.0225476.g002}

10.1371/journal.pone.0225476.t001

###### Demographic and clinical characteristics of pregnancy cohort (living with HIV) registered for ante-natal care in Mazowe District, Zimbabwe (2017).

![](pone.0225476.t001){#pone.0225476.t001g}

  Characteristics[\*](#t001fn001){ref-type="table-fn"}          N                 (%)    
  ------------------------------------------------------------- ----------------- ------ --------
  Age group (years)                                                                      
                                                                15--19            46     (4.1)
                                                                20--24            166    (14.9)
                                                                25--29            283    (25.4)
                                                                30--49            617    (55.5)
  Gestational Age at ANC registration                                                    
                                                                = \<12 weeks      197    (17.7)
                                                                13--24 weeks      669    (60.2)
                                                                25--32 weeks      171    (15.4)
                                                                \>32 weeks        44     \(4\)
                                                                Missing           31     (2.8)
  Gravida                                                                                
                                                                1                 78     \(7\)
                                                                2                 188    (16.9)
                                                                3                 294    (26.4)
                                                                4                 326    (29.3)
                                                                \>5               224    (20.1)
                                                                Missing           2      (0.2)
  Facility                                                                               
                                                                Clinic            327    (29.4)
                                                                Hospital          785    (70.6)
  Anaemia[\*\*](#t001fn003){ref-type="table-fn"}                                         
                                                                No Anaemia        798    (71.8)
                                                                Anaemia           111    \(10\)
                                                                Severe Anaemia    6      (0.5)
                                                                Missing           197    (17.7)
  Hypertension (HTN)[\*\*\*](#t001fn004){ref-type="table-fn"}                            
                                                                Normal            640    (57.6)
                                                                Pre-HTN           355    (31.9)
                                                                Stage 1 HTN       92     (8.3)
                                                                Stage 2 HTN       13     (1.2)
                                                                Missing           12     (1.1)
  Weight (kgs)                                                                           
                                                                30--44            20     (1.8)
                                                                45--59            495    (44.5)
                                                                \> = 60           583    (52.4)
                                                                Missing           14     (1.3)
  ART Status                                                                             
                                                                Already on ART    1000   (89.9)
                                                                Newly Initiated   112    (10.1)
  WHO Staging                                                                            
                                                                Stage 1           208    (18.7)
                                                                Stage 2           271    (24.4)
                                                                Stage 3           98     (8.8)
                                                                Stage 4           4      (0.4)
                                                                Missing           531    (47.8)
  Partner HIV Status                                                                     
                                                                Positive          250    (22.5)
                                                                Negative          209    (18.8)
                                                                Unknown           653    (58.7)
  Syphilis Test                                                                          
                                                                Positive          56     \(5\)
                                                                Negative          939    (84.4)
                                                                Not recorded      117    (10.5)

\*Characteristics as at first ANC visit

ANC--Antenatal care; ART--Antiretroviral therapy; HTN- Hypertension; WHO- World Health Organization

\*\* No anaemia \> = 11 hbg%; Anaemia = 7--11 hbg%; Severe Anaemia\<7 hbg%

\*\*\* Normal is \<120/80; pre-HTN is 120-139/80-89; Stage1 HTN is 140-159/90-109; Stage 2 HTN is \> = 160/110

VL testing {#sec018}
----------

Of 1112 women, VL results were available for 354 (31.8%, 95% CI: 29.2--34.6). Of 354, a total of 334 (94.4%) were virally suppressed and 13 out of 20 virally non-suppressed women underwent repeat VL testing. Of 13, VL results were available for ten (nine were virally suppressed). Of 1112, VL results were available between 32 weeks' gestation and child birth in 31 (2.8%, 95% CI: 1.9, 3.9) women.

Of 354, 113 (31.9%) underwent testing during pregnancy, 124 (35%) within six months of child birth and for 117 (33.1%), dates were not available to classify when testing was done (**[Fig 3](#pone.0225476.g003){ref-type="fig"}**). Of 354, only 125 had the dates recorded to calculate median TAT. The median TAT from specimen collection to result receipt by PBF women was 93 days (IQR 19.3--255).

![Flowchart describing the viral load testing among the pregnancy cohort (living with HIV and on ART) included in the study, Mazowe district, Zimbabwe (2017).\
VL- Viral load. Included those i) already on antiretroviral therapy before pregnancy and ii) newly diagnosed with HIV during antenatal care and on antiretroviral therapy for at least three months.](pone.0225476.g003){#pone.0225476.g003}

Factors associated with uptake of VL testing {#sec019}
--------------------------------------------

**[Table 2](#pone.0225476.t002){ref-type="table"}** summarizes the factors associated with uptake of VL testing. On adjusted analysis, facility and WHO staging were significantly associated. When compared to hospitals, PBF women registered for ANC in clinics were 36% less likely to have a VL result \[aRR: 0.64 (95% CI: 0.53, 0.76)\]. When compared to WHO stage 1, women in stage 2 were 29% more likely to have a VL result \[aRR: 1.29 (95% CI: 1.07, 1.55)\].

10.1371/journal.pone.0225476.t002

###### Factors associated with uptake of VL test among the pregnancy cohort (living with HIV and on ART) registered for ante-natal care in Mazowe district, Zimbabwe (2017).

![](pone.0225476.t002){#pone.0225476.t002g}

  Factors                                                        Total             Viral Load uptake   RR    (95%CI)   aRR[\*](#t002fn002){ref-type="table-fn"}   (95%CI)                                                                                    
  -------------------------------------------------------------- ----------------- ------------------- ----- --------- ------------------------------------------ --------------------------------------------------- -------------------------------------- --------------------------------------------------
  Age group (years)                                                                                                                                                                                                                                          
                                                                 15--19            46                  8     (17.4)    0.50                                       (0.26, 0.94)[\^](#t002fn006){ref-type="table-fn"}   0.70                                   (0.35,1.43)
                                                                 20--24            166                 46    (27.7)    0.79                                       (0.60,1.03)                                         0.79                                   (0.59,1.05)
                                                                 25--29            283                 83    (29.3)    0.83                                       (0.68,1.03)                                         0.95                                   (0.78,1.17)
                                                                 30--49            617                 217   (35.2)    Ref                                                                                                                                   
  Gestational Age at ANC registration                                                                                                                                                                                                                        
                                                                 = \<12 weeks      197                 57    (28.9)    Ref                                                                                                                                   
                                                                 13--24 weeks      669                 227   (33.9)    1.17                                       (0.92,1.50)                                         0.97                                   (0.79,1.18)
                                                                 25--32 weeks      171                 46    (26.9)    0.93                                       (0.67,1.29)                                         0.85                                   (0.64,1.12)
                                                                 \>32 weeks        44                  9     (20.5)    0.71                                       (0.38,1.32)                                         0.67                                   (0.37,1.19)
                                                                 Missing           31                  15    (48.4)    1.67                                       (1.09,2.56)[\^](#t002fn006){ref-type="table-fn"}    1.41                                   (0.90,2.23)
  Gravida                                                                                                                                                                                                                                                    
                                                                 1                 78                  18    (23.1)    0.57                                       (0.37,0.89)[\^](#t002fn006){ref-type="table-fn"}    0.81                                   (0.48,1.34)
                                                                 2                 188                 53    (28.2)    0.70                                       (0.53,0.93)[\^](#t002fn006){ref-type="table-fn"}    0.93                                   (0.70,1.22)
                                                                 3                 294                 96    (32.7)    0.81                                       (0.65,1.02)                                         1.07                                   (0.87,1.31)
                                                                 4                 326                 96    (29.4)    0.73                                       (0.58,0.92)[\^](#t002fn006){ref-type="table-fn"}    0.90                                   (0.74,1.09)
                                                                 \>5               224                 90    (40.2)    Ref                                                                                                                                   
                                                                 Missing           2                   1     (50.0)    \-\-\--                                                                                        1.25                                   (0.82,1.91)
  Facility                                                                                                                                                                                                                                                   
                                                                 Clinic            785                 208   (26.5)    0.59                                       (0.50,0.70)[\^](#t002fn006){ref-type="table-fn"}    0.64                                   (0.53,0.76)[\^](#t002fn006){ref-type="table-fn"}
                                                                 Hospital          327                 146   (44.6)    Ref                                                                                                                                   
  Anaemia[\*\*](#t002fn004){ref-type="table-fn"}                                                                                                                                                                                                             
                                                                 No Anaemia        798                 253   (31.7)    Ref                                                                                                                                   
                                                                 Anaemia           111                 50    (45.0)    1.42                                       (1.13,1.79)[\^](#t002fn006){ref-type="table-fn"}    1.08                                   (0.87,1.34)
                                                                 Severe Anaemia    6                   1     (16.7)    0.53                                       (0.09,3.16)                                         0.59                                   (0.20,1.70)
                                                                 Missing           197                 50    (25.4)    0.80                                       (0.62,1.04)                                         0.84                                   (0.67,1.07)
  Hypertension (HTN) [\*\*\*](#t002fn005){ref-type="table-fn"}                                                                                                                                                                                               
                                                                 Normal            640                 196   (30.6)    Ref                                                                                            [†](#t002fn003){ref-type="table-fn"}   
                                                                 Pre-HTN           355                 123   (34.6)    1.13                                       (0.94,1.36)                                                                                
                                                                 Stage 1 HTN       92                  28    (30.4)    0.99                                       (0.71,1.38)                                                                                
                                                                 Stage 2 HTN       13                  5     (38.5)    1.26                                       (0.63,2.52)                                                                                
                                                                 Missing           12                  2     (16.7)    0.54                                       (0.15,1.94)                                                                                
  Weight (kgs)                                                                                                                                                                                                                                               
                                                                 30--44            20                  6     (30.0)    0.96                                       (0.48,1.89)                                         [†](#t002fn003){ref-type="table-fn"}   
                                                                 45--59            495                 161   (32.5)    1.04                                       (0.87,1.23)                                                                                
                                                                 \> = 60           583                 183   (31.4)    Ref                                                                                                                                   
                                                                 Missing           14                  4     (28.6)    0.91                                       (0.39,2.10)                                                                                
  ART Status                                                                                                                                                                                                                                                 
                                                                 Already on ART    1000                307   (30.7)    0.73                                       (0.58,0.93)[\^](#t002fn006){ref-type="table-fn"}    0.98                                   (0.76,1.25)
                                                                 Newly Initiated   112                 47    (42.0)    Ref                                                                                                                                   
  WHO Staging                                                                                                                                                                                                                                                
                                                                 Stage 1           208                 97    (46.6)    Ref                                                                                                                                   
                                                                 Stage 2           271                 159   (58.7)    1.26                                       (1.05,1.50)[\^](#t002fn006){ref-type="table-fn"}    1.29                                   (1.07,1.55)[\^](#t002fn006){ref-type="table-fn"}
                                                                 Stage 3           98                  59    (60.2)    1.29                                       (1.04,1.60)[\^](#t002fn006){ref-type="table-fn"}    1.19                                   (0.96,1.49)
                                                                 Stage 4           4                   1     (25.0)    0.54                                       (0.10,2.95)                                         0.54                                   (0.12,2.51)
                                                                 Missing           531                 38    (7.2)     0.15                                       (0.11,0.22)[\^](#t002fn006){ref-type="table-fn"}    0.15                                   (0.11,0.22)[\^](#t002fn006){ref-type="table-fn"}
  Partner HIV Status                                                                                                                                                                                                                                         
                                                                 Positive          250                 82    (32.8)    Ref                                                                                                                                   
                                                                 Negative          209                 54    (25.8)    0.79                                       (0.59,1.05)                                         0.83                                   (0.64,1.09)
                                                                 Unknown           653                 218   (33.4)    1.02                                       (0.83,1.25)                                         0.94                                   (0.78,1.13)
  Syphilis Test                                                                                                                                                                                                                                              
                                                                 Positive          56                  17    (30.4)    Ref                                                                                                                                   
                                                                 Negative          939                 294   (31.3)    1.03                                       (0.69,1.55)                                         [†](#t002fn003){ref-type="table-fn"}   
                                                                 Not recorded      117                 43    (36.8)    1.21                                       (0.76,1.92)                                                                                

Row percentage. ANC--Antenatal Care; HTN- Hypertension; ART--Antiretroviral therapy; WHO- World Health Organization; RR--relative risk; aRR--adjusted relative risk; CI- confidence interval

\* Adjusted analysis conducted using modified Poisson regression

† weight, hypertension and syphilis test were not included in the regression model as their unadjusted p value was \>0.2

\*\*Anaemia---No anaemia \> = 11 hbg%; Anaemia = 7--11 hbg%; Severe Anaemia\<7 hbg%

\*\*\* Hypertension---Normal is \<120/80; pre-HTN is 120-139/80-89; Stage1 HTN is 140-159/90-109; Stage 2 HTN is \> = 160/110

\^p\<0.05

Missing data {#sec020}
------------

Of 1112 women in pregnancy cohort, as per information available in the records, we could assign only 453(40.7%) to the breastfeeding cohort (mother on ART and child alive at six months post child birth). There were various reasons for this which include missing data for delivery date \[n = 631 (56.7%)\] and ART outcome at six months post child birth \[n = 629 (56.6%)\]. Of 354 VL results available, dates for sending VL specimen, receipt of results at facility and receipt of results by PBF women were missing in 49(13.8%), 328 (92.7%) and 191(54.0%) instances, respectively.

Discussion {#sec021}
==========

This is one of the first cohort-wise assessments of HIV VL testing amongst PBF women living with HIV in programmatic settings. In a rural district of Zimbabwe, we found poor data documentation in the routine registers, low testing uptake and long turnaround times. Most of them with a result were virally suppressed.

Key findings {#sec022}
------------

The study has many programme relevant findings. First, there was poor routine data documentation, almost half of the records had missing data. We could not report VL uptake separately for the pregnancy and breast feeding cohort as we did not have the correct denominator to distinguish the two groups due to missing dates. In almost half of the records, we observed missing delivery date, date VL specimen taken and date results were received by the PBF woman. We could not provide the breakdown of the TAT for VL testing due to missing dates. The ART start date was missing for many pregnant women who were already on ART. Hence, we could not analyse the association between duration of ART and VL testing. In a PMTCT study done in Harare city, Zimbabwe, 90% of study population lacked adequate information to determine whether mother belonged to the high risk MTCT group or not \[[@pone.0225476.ref017]\].

Second, VL testing uptake was low with unacceptably long turnaround times. Long TATs prevent effective utilization of VL results for clinical decision making. It is very much possible that long TATs can in turn have a negative effect on VL testing uptake. In low- and middle-income countries, low uptake of healthcare services and adherence to treatment and monitoring guidelines is affected by fragile healthcare systems and lack of resources \[[@pone.0225476.ref018]\]. Similar to our study, in Kenya, VL specimen and test results required distant shipments from the clinics to the testing laboratory and back \[[@pone.0225476.ref019]\].

The VL testing uptake was lower when compared to other studies in the region. In programmatic setting in Mozambique, VL testing uptake was 40% in general population \[[@pone.0225476.ref010]\]. Among pregnant women living with HIV in a predominantly rural setting in Swaziland, the VL uptake was 67% \[[@pone.0225476.ref020]\]. The Swaziland study was a pilot on the feasibility of option B+ with specially trained staff that included mobile medical doctors attending to clinically complicated patients. Therefore the circumstance were different from our study which dealt with routinely collected data \[[@pone.0225476.ref021],[@pone.0225476.ref022]\].

Most studies report TAT from specimen collection to processing time in the laboratory or intra-laboratory TAT. A study in Kenya reported TAT of 21 days from specimen collection to results dispatch from laboratory, whilst a study in Malawi reported intra-laboratory TAT of 18 days \[[@pone.0225476.ref023],[@pone.0225476.ref024]\]. This may not be comparable with our study as we reported TAT from specimen collection at facility to result receipt by PBF women (this includes receipt at laboratory, dispatch results and receipt of results at the facility).

Third, satisfactory viral suppression in our study (higher than UNAIDS target of 90% for all women on ART) should be interpreted with caution as majority of PBF women did not undergo VL testing. This might not be the true picture of VL suppression among those on ART. Viral suppression of 84% in Malawi (from a randomized controlled trial) and 85% in rural South Africa (programmatic setting) should also be interpreted with caution as the VL testing uptake was not reported \[[@pone.0225476.ref011],[@pone.0225476.ref025]\].

Fourth, we found a significantly lower uptake of VL testing in clinics as compared to hospitals. Shortage of trained staff, poor working conditions, low staff morale and poor management have been implicated for low uptake of healthcare services in remote rural areas in Sub Saharan Africa \[[@pone.0225476.ref022],[@pone.0225476.ref026]\]. Recent initiatives such as quality improvement have improved provision and uptake of ANC services in hard to reach areas \[[@pone.0225476.ref022],[@pone.0225476.ref027]\]. In clinics in rural Kenya, quality improvement approaches increased adherence to standards of ANC from \<40% to 80--100% \[[@pone.0225476.ref022]\]. Similarly, rural clinics in Zimbabwe can be prioritised for quality improvement initiatives for PMTCT indicators.

Implications for policy and practice {#sec023}
------------------------------------

There is a need to prioritize VL testing in PBF women through improved monitoring and supervision. The first step is to urgently improve the completeness of routine data collected. Every healthcare worker at the health facility should be trained in routine data collection. This activity can ride on the existing PMTCT and ART mentoring programme. The routine data collection tools can also be introduced as part of pre-service training for nurses as they man primary care facilities in Zimbabwe.

Additionally, the reports of quarterly supportive supervision conducted by district management in selected facilities should be utilized to improve the data quality in all the facilities of the district. The tools used for support and supervision conducted by the district team should include assessment on data completeness, timeliness, accuracy and consistency in the registers.

The submission of monthly return form has been successful with completion rates consistently above 95%, this is because there is proactive monitoring and follow up of these forms since they are part of the nationally reported indicators. In addition to already present indicators in the monthly return form \[number of pregnant women living with HIV newly registered for ANC that are ART naïve (a); and number of pregnant women living with HIV newly registered for ANC that are already on ART (b)\], there is a need to add another indicator 'number of VL specimen of pregnant women sent (c)'. At the district, provincial and national level, VL testing uptake during pregnancy can be reviewed using the formula 'c ≥ 0.85\*a + 0.5\*b' (assuming 85% of ART naïve pregnant women are retained in ART care at three months and 50% of pregnant women already on ART do not have a VL result in last six months). If 'c' is less than '0.85\*a + 0.5\*b', feedback should be sent and corrective actions taken. Similarly, testing uptake during breast feeding may be reviewed.

Second, point of care machines or information technology to transmit the results is urgently required to lower the TAT. For early infant diagnosis of HIV in Zimbabwe, point of care assay has been found to be cost-effective than conventional testing \[[@pone.0225476.ref028]\]. The same may be applicable for VL testing as well. The country can leverage on the already available point of care devices in some rural clinics to offer HIV VL testing.

Finally, there is an urgent need for qualitative systematic enquiry to understand the possible reasons and suggested solutions from the user perspective (PBF mother and facility staff).

Limitations {#sec024}
-----------

There were two limitations. In addition to the missing data which is a key limitation, the study did not look at health systems related factors and other socio-demographic characters which can affect service uptake. This was not routinely collected and therefore, beyond the scope of this study.

Conclusion {#sec025}
==========

There is a critical need to strengthen the recording and local utilisation of routine clinic data in order to successfully monitor progress of healthcare services provided.VL testing uptake was low with turnaround times unacceptably long among PBF women on 'option B+' in Mazowe district, Zimbabwe. Viral load suppression was satisfactory among those tested. There is an urgent need to prioritize VL monitoring in PBF women and consider use of point of care assays. These activities are urgently needed if Zimbabwe is to meet the 2022 national target of reducing MTCT to less than five percent.
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